3-carboranyl thymidine analogues (3CTAs) and other boronated nucleosides for boron neutron capture therapy

Youngjoo Byun; Sureshbabu Narayanasamy; Jayaseharan Johnsamuel; Achintya K. Bandyopadhyaya; Rohit Tiwari; Ashraf S. Al-Madhoun; Rolf F. Barth; Staffan Eriksson; Werner Tjarks

doi:10.2174/187152006776119171

3-carboranyl thymidine analogues (3CTAs) and other boronated nucleosides for boron neutron capture therapy

Youngjoo Byun, Sureshbabu Narayanasamy, Jayaseharan Johnsamuel, Achintya K. Bandyopadhyaya, Rohit Tiwari, Ashraf S. Al-Madhoun, Rolf F. Barth, Staffan Eriksson, Werner Tjarks

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

One category of boron neutron capture therapy (BNCT) agents that has received extensive attention during recent years is 3-carboranyl thymidine analogues (3CTAs). These molecules are phosphorylated to the corresponding 5′-monophosphates by human thymidine kinase 1 (TK1), an enzyme that is up-regulated in dividing malignant cells. Thus, these phosphorylated molecules are selectively entrapped in tumor cells due to the acquired negative charge. This review will analyze design strategies applied for the synthesis of boron-containing nucleosides in general and in particular reference to 3CTAs. Results of biological studies with these molecules will be discussed.

Original language	English (US)
Pages (from-to)	127-144
Number of pages	18
Journal	Anti-Cancer Agents in Medicinal Chemistry
Volume	6
Issue number	2
DOIs	https://doi.org/10.2174/187152006776119171
State	Published - Mar 2006
Externally published	Yes

Keywords

3-carboranyl thymidine analogues
3CTAs
Boron neutron capture therapy
Carboranes
N5-2OH
Nucleosides
Thymidine kinase

ASJC Scopus subject areas

Cancer Research
Molecular Medicine
Pharmacology

Access to Document

10.2174/187152006776119171

Cite this

@article{2f14855fcc1849d49d7892bda6b8f950,

title = "3-carboranyl thymidine analogues (3CTAs) and other boronated nucleosides for boron neutron capture therapy",

abstract = "One category of boron neutron capture therapy (BNCT) agents that has received extensive attention during recent years is 3-carboranyl thymidine analogues (3CTAs). These molecules are phosphorylated to the corresponding 5′-monophosphates by human thymidine kinase 1 (TK1), an enzyme that is up-regulated in dividing malignant cells. Thus, these phosphorylated molecules are selectively entrapped in tumor cells due to the acquired negative charge. This review will analyze design strategies applied for the synthesis of boron-containing nucleosides in general and in particular reference to 3CTAs. Results of biological studies with these molecules will be discussed.",

keywords = "3-carboranyl thymidine analogues, 3CTAs, Boron neutron capture therapy, Carboranes, N5-2OH, Nucleosides, Thymidine kinase",

author = "Youngjoo Byun and Sureshbabu Narayanasamy and Jayaseharan Johnsamuel and Bandyopadhyaya, {Achintya K.} and Rohit Tiwari and Al-Madhoun, {Ashraf S.} and Barth, {Rolf F.} and Staffan Eriksson and Werner Tjarks",

year = "2006",

month = mar,

doi = "10.2174/187152006776119171",

language = "English (US)",

volume = "6",

pages = "127--144",

journal = "Anti-Cancer Agents in Medicinal Chemistry",

issn = "1871-5206",

publisher = "Bentham Science Publishers B.V.",

number = "2",

}

TY - JOUR

T1 - 3-carboranyl thymidine analogues (3CTAs) and other boronated nucleosides for boron neutron capture therapy

AU - Byun, Youngjoo

AU - Narayanasamy, Sureshbabu

AU - Johnsamuel, Jayaseharan

AU - Bandyopadhyaya, Achintya K.

AU - Tiwari, Rohit

AU - Al-Madhoun, Ashraf S.

AU - Barth, Rolf F.

AU - Eriksson, Staffan

AU - Tjarks, Werner

PY - 2006/3

Y1 - 2006/3

N2 - One category of boron neutron capture therapy (BNCT) agents that has received extensive attention during recent years is 3-carboranyl thymidine analogues (3CTAs). These molecules are phosphorylated to the corresponding 5′-monophosphates by human thymidine kinase 1 (TK1), an enzyme that is up-regulated in dividing malignant cells. Thus, these phosphorylated molecules are selectively entrapped in tumor cells due to the acquired negative charge. This review will analyze design strategies applied for the synthesis of boron-containing nucleosides in general and in particular reference to 3CTAs. Results of biological studies with these molecules will be discussed.

AB - One category of boron neutron capture therapy (BNCT) agents that has received extensive attention during recent years is 3-carboranyl thymidine analogues (3CTAs). These molecules are phosphorylated to the corresponding 5′-monophosphates by human thymidine kinase 1 (TK1), an enzyme that is up-regulated in dividing malignant cells. Thus, these phosphorylated molecules are selectively entrapped in tumor cells due to the acquired negative charge. This review will analyze design strategies applied for the synthesis of boron-containing nucleosides in general and in particular reference to 3CTAs. Results of biological studies with these molecules will be discussed.

KW - 3-carboranyl thymidine analogues

KW - 3CTAs

KW - Boron neutron capture therapy

KW - Carboranes

KW - N5-2OH

KW - Nucleosides

KW - Thymidine kinase

UR - http://www.scopus.com/inward/record.url?scp=33645826248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645826248&partnerID=8YFLogxK

U2 - 10.2174/187152006776119171

DO - 10.2174/187152006776119171

M3 - Article

C2 - 16529536

AN - SCOPUS:33645826248

SN - 1871-5206

VL - 6

SP - 127

EP - 144

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

IS - 2

ER -

3-carboranyl thymidine analogues (3CTAs) and other boronated nucleosides for boron neutron capture therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this